P
Paul D. Smith
Researcher at AstraZeneca
Publications - 218
Citations - 12256
Paul D. Smith is an academic researcher from AstraZeneca. The author has contributed to research in topics: Selumetinib & Cancer. The author has an hindex of 53, co-authored 207 publications receiving 10843 citations. Previous affiliations of Paul D. Smith include National Institutes of Health & Institute of Cancer Research.
Papers
More filters
Journal ArticleDOI
Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer
Mariano Ponz-Sarvise,Vincenzo Corbo,Hervé Tiriac,Dannielle D. Engle,Kristopher K. Frese,Tobiloba E. Oni,Tobiloba E. Oni,Chang-Il Hwang,Daniel Öhlund,Iok In Christine Chio,Lindsey A. Baker,Dea Filippini,Kevin Wright,Tashinga E. Bapiro,Pearl S. Huang,Paul D. Smith,Kenneth H. Yu,Duncan I. Jodrell,Young-Kyu Park,David A. Tuveson +19 more
TL;DR: Analyses of normal and tumor pancreatic organoids revealed the importance of ERBB activation during MEK and AKT blockade primarily in the malignant cultures, and the lack of ER BB hyperactivation in normal organoids suggests a larger therapeutic index.
Journal ArticleDOI
Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC).
Pasi A. Jänne,Alice T. Shaw,José Rodrigues Pereira,Gaelle Jeannin,Johan Vansteenkiste,Carlos H. Barrios,Fabio Franke,Lynda Grinsted,Paul D. Smith,Victoria Zazulina,Ian C. Smith,Lucio Crinò +11 more
TL;DR: The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), objective response rate (RR), duration of response, change in tumor size, proportion of patients alive and progression- free at 6 mo, and safety and tolerability.
Journal ArticleDOI
Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer
Hyejin Choi,Jiehui Deng,Shuai Li,Tarik Silk,Lauren Dong,Elliott J. Brea,Sean Houghton,David Redmond,Hong Zhong,Jonathan Boiarsky,Esra A. Akbay,Paul D. Smith,Taha Merghoub,Kwok-Kin Wong,Jedd D. Wolchok +14 more
TL;DR: Pulsatile MEKi treatment combined with CTLA-4 blockade prolongs survival in mice bearing tumors with mutant Kras and shows the importance of a combinatorial therapeutic strategy using pulsatile targeted therapy together with immunotherapy to optimally enhance tumor delay and promote long-term anti-tumor immunity.
Journal ArticleDOI
Intraoperative photodynamic therapy for malignant mesothelioma
Harvey I. Pass,Zelig Tochner,Thomas F. DeLaney,Paul D. Smith,Walter S. Friauf,Eli Glatstein,William D. Travis +6 more
Journal ArticleDOI
Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations.
Jacqueline H. Starrett,Alexis A. Guernet,Maria Emanuela Cuomo,Kamrine E. Poels,Iris K. van Alderwerelt van Rosenburgh,Amy Nagelberg,Dylan Farnsworth,Kristin Price,Hina Khan,Kumar Dilip Ashtekar,Mmaserame Gaefele,Deborah Ayeni,Tyler F. Stewart,Alexandra Kuhlmann,Susan M. Kaech,Arun M. Unni,Robert J. Homer,William W. Lockwood,Franziska Michor,Sarah B. Goldberg,Mark A. Lemmon,Paul D. Smith,Darren Cross,Katerina Politi +23 more
TL;DR: Analysis of circulating free DNA data from patients and modeled acquired resistance to osimertinib in transgenic mouse models of EGFRL858R-induced lung adenocarcinoma found that it is mediated largely through secondary mutations in EGFR—either C797S or L718V/Q.